|
TW586934B
(en)
*
|
1997-05-19 |
2004-05-11 |
Sumitomo Pharma |
Immunopotentiating composition
|
|
US7241730B2
(en)
|
1998-08-27 |
2007-07-10 |
Universitat Zurich |
Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides
|
|
US7615373B2
(en)
*
|
1999-02-25 |
2009-11-10 |
Virginia Commonwealth University Intellectual Property Foundation |
Electroprocessed collagen and tissue engineering
|
|
US20040018226A1
(en)
*
|
1999-02-25 |
2004-01-29 |
Wnek Gary E. |
Electroprocessing of materials useful in drug delivery and cell encapsulation
|
|
US20020081732A1
(en)
*
|
2000-10-18 |
2002-06-27 |
Bowlin Gary L. |
Electroprocessing in drug delivery and cell encapsulation
|
|
US6083933A
(en)
*
|
1999-04-19 |
2000-07-04 |
Stellar International Inc. |
Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
|
|
CA2371462C
(en)
*
|
1999-04-22 |
2009-09-15 |
Jason C. Schense |
Modified protein matrices
|
|
DE69929323T2
(de)
*
|
1999-04-22 |
2006-09-07 |
Eidgenössische Technische Hochschule (ETH) |
Kontrollierte abgabe der wachstumsfaktoren von heparin enthaltenden matrizen
|
|
AU2001288692A1
(en)
*
|
2000-09-01 |
2002-03-13 |
Virginia Commonwealth University Intellectual Property Foundation |
Electroprocessed fibrin-based matrices and tissues
|
|
CA2325842C
(en)
*
|
2000-11-02 |
2007-08-07 |
Lisa Mckerracher |
Methods for making and delivering rho-antagonist tissue adhesive formulations to the injured mammalian central and peripheral nervous systems and uses thereof
|
|
US7182944B2
(en)
*
|
2001-04-25 |
2007-02-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of increasing distribution of nucleic acids
|
|
US7906102B2
(en)
|
2001-10-03 |
2011-03-15 |
Vanderbilt University |
Ligands to radiation-induced molecules
|
|
WO2003041723A1
(de)
|
2001-11-12 |
2003-05-22 |
Reinmueller Johannes |
Pharmazeutische anwendungen von hyaluronsäure-präparaten
|
|
WO2003066083A1
(en)
*
|
2002-02-04 |
2003-08-14 |
Sumitomo Pharmaceuticals Company, Limited |
Preparations for treating bone fracture or bone loss or elevating bone density
|
|
US20030216315A1
(en)
|
2002-02-13 |
2003-11-20 |
Duke University |
Modulation of immune response by non-peptide binding stress response polypeptides
|
|
CA2500661A1
(en)
|
2002-10-01 |
2004-04-15 |
Chiron Corporation |
Anti-cancer and anti-infectious disease compositions and methods for using same
|
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
|
US20040161476A1
(en)
|
2003-02-19 |
2004-08-19 |
Hahn Sungtack Samuel |
Cystitis treatment with high dose chondroitin sulfate
|
|
CN105820160B
(zh)
|
2003-11-05 |
2019-02-12 |
萨可德生物科学公司 |
细胞粘着调节剂
|
|
FR2862878B1
(fr)
*
|
2003-11-27 |
2006-03-24 |
Sofradim Production |
Substrat metallique revetu d'une composition de collagene et de polysaccharides, procede et applications
|
|
GB0402131D0
(en)
|
2004-01-30 |
2004-03-03 |
Isis Innovation |
Delivery method
|
|
US20060039949A1
(en)
*
|
2004-08-20 |
2006-02-23 |
Nycz Jeffrey H |
Acetabular cup with controlled release of an osteoinductive formulation
|
|
US20060045902A1
(en)
*
|
2004-09-01 |
2006-03-02 |
Serbousek Jon C |
Polymeric wrap for in vivo delivery of osteoinductive formulations
|
|
US20060057184A1
(en)
*
|
2004-09-16 |
2006-03-16 |
Nycz Jeffrey H |
Process to treat avascular necrosis (AVN) with osteoinductive materials
|
|
US8137664B2
(en)
*
|
2005-02-02 |
2012-03-20 |
Sdgi Holdings, Inc. |
Method and kit for repairing a defect in bone
|
|
WO2006130217A2
(en)
*
|
2005-04-01 |
2006-12-07 |
The Regents Of The University Of California |
Substituted phosphate esters of nucleoside phosphonates
|
|
EP1866319B1
(de)
|
2005-04-01 |
2011-11-23 |
The Regents of The University of California |
Phosphono-pent-2-en-1-yl-nukleoside und analoga
|
|
PL2444079T3
(pl)
|
2005-05-17 |
2017-07-31 |
Sarcode Bioscience Inc. |
Kompozycje i sposoby leczenia chorób oczu
|
|
AU2006332340B2
(en)
|
2005-12-30 |
2013-09-26 |
Zensun (Shanghai) Science & Technology, Co., Ltd. |
Extended release of neuregulin for improved cardiac function
|
|
ES2450065T3
(es)
*
|
2006-03-01 |
2014-03-21 |
Biogen Idec Ma Inc. |
Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
|
|
EP2001446A2
(de)
*
|
2006-03-13 |
2008-12-17 |
Encysive Pharmaceuticals, Inc |
Sitaxsentan-natrium-formulierungen
|
|
BRPI0708879A2
(pt)
*
|
2006-03-13 |
2011-06-14 |
Encysive Pharmaceuticals |
peocessos e composiÇÕes para o tratamento de insufiÊncia cardÍaca diastàlica
|
|
KR101419554B1
(ko)
*
|
2006-03-13 |
2014-07-17 |
교린 세이야꾸 가부시키 가이샤 |
Ｇｓｋ３ 억제제로서 아미노퀴놀론
|
|
US20080026061A1
(en)
*
|
2006-06-22 |
2008-01-31 |
Reichwein John F |
Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
|
|
PT2066662E
(pt)
|
2006-09-21 |
2013-02-13 |
Kyorin Seiyaku Kk |
Inibidores de serina-hidrolase
|
|
CA2666149A1
(en)
|
2006-10-19 |
2008-04-24 |
Auspex Pharmaceuticals, Inc. |
Substituted indoles
|
|
US20100137421A1
(en)
*
|
2006-11-08 |
2010-06-03 |
Emmanuel Theodorakis |
Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
|
|
KR20090086115A
(ko)
*
|
2006-12-22 |
2009-08-10 |
엔싸이시브 파마슈티칼즈 인코퍼레이티드 |
Ｃ３ａ 수용체의 조정제 및 이의 사용 방법
|
|
HRP20110713T1
(hr)
*
|
2007-02-28 |
2011-11-30 |
Conatus Pharmaceuticals |
Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
|
|
WO2008106167A1
(en)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
|
|
AU2008251773A1
(en)
|
2007-03-15 |
2008-11-20 |
Auspex Pharmaceuticals, Inc. |
Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
|
|
US7892776B2
(en)
|
2007-05-04 |
2011-02-22 |
The Regents Of The University Of California |
Screening assay to identify modulators of protein kinase A
|
|
MX354786B
(es)
|
2007-06-04 |
2018-03-21 |
Synergy Pharmaceuticals Inc |
Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
AU2008274941A1
(en)
*
|
2007-07-12 |
2009-01-15 |
Tragara Pharmaceuticals, Inc. |
Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
|
|
BRPI0816798A2
(pt)
*
|
2007-09-11 |
2016-10-11 |
Activx Biosciences Inc |
composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
|
|
CN101855229A
(zh)
|
2007-09-12 |
2010-10-06 |
埃迪威克斯生物科学公司 |
作为gsk-3抑制剂的螺环状氨基喹诺酮
|
|
CA2702984C
(en)
*
|
2007-10-19 |
2017-04-11 |
Sarcode Corporation |
Compositions and methods for treatment of diabetic retinopathy
|
|
CA2745339C
(en)
|
2007-12-24 |
2016-06-28 |
The University Of Queensland |
Coating method
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
CA2749347C
(en)
*
|
2008-02-07 |
2018-03-27 |
The University Of Queensland |
Patch production
|
|
HUE025197T2
(en)
|
2008-03-17 |
2016-02-29 |
Ambit Biosciences Corp |
Quinazoline derivatives as RAF kinase modulators and methods for their use
|
|
WO2009139817A2
(en)
|
2008-04-15 |
2009-11-19 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
WO2009128932A1
(en)
*
|
2008-04-15 |
2009-10-22 |
Sarcode Corporation |
Delivery of lfa-1 antagonists to the gastrointestinal system
|
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
|
BRPI0912842A8
(pt)
*
|
2008-05-20 |
2019-01-29 |
Cerenis Therapeutics Holding |
composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
|
|
EP2294415A4
(de)
*
|
2008-05-23 |
2011-10-05 |
Univ Queensland |
Analytnachweis mittels mikronadelpflaster mit analytselektiven reagentien
|
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
WO2010014134A1
(en)
|
2008-07-02 |
2010-02-04 |
Idenix Pharamaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
EP2321341B1
(de)
|
2008-07-16 |
2017-02-22 |
Synergy Pharmaceuticals Inc. |
Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
|
|
US20110200525A1
(en)
*
|
2008-10-09 |
2011-08-18 |
Patz Jr Edward F |
Vhh antibody fragments for use in the detection and treatment of cancer
|
|
WO2010071918A1
(en)
|
2008-12-22 |
2010-07-01 |
The University Of Queensland |
Patch production
|
|
CA2748389A1
(en)
|
2008-12-31 |
2010-07-08 |
Scynexis, Inc. |
Derivatives of cyclosporin a
|
|
WO2010088450A2
(en)
|
2009-01-30 |
2010-08-05 |
Celladon Corporation |
Methods for treating diseases associated with the modulation of serca
|
|
US8568793B2
(en)
|
2009-02-11 |
2013-10-29 |
Hope Medical Enterprises, Inc. |
Sodium nitrite-containing pharmaceutical compositions
|
|
PL2401267T3
(pl)
|
2009-02-27 |
2014-06-30 |
Ambit Biosciences Corp |
Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
|
|
WO2010101967A2
(en)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Phosphothiophene and phosphothiazole hcv polymerase inhibitors
|
|
MX2011009413A
(es)
|
2009-03-11 |
2011-10-21 |
Ambit Biosciences Corp |
Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
|
|
BRPI1008974A2
(pt)
*
|
2009-03-11 |
2017-06-06 |
Kyorin Seiyaku Kk |
composto, composição farmacêutica, e, método para tratar, prevenir ou melhorar uma doença mediada com gsk-3
|
|
US8461158B2
(en)
|
2009-03-27 |
2013-06-11 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
WO2010110686A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics Limited |
Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
|
|
PL2421829T3
(pl)
|
2009-04-22 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
2,5-dipodstawione arylosulfonamidy jako antagoniści CCR3
|
|
WO2010123959A2
(en)
|
2009-04-22 |
2010-10-28 |
Axikin Pharmaceuticals, Inc. |
2,5-disubstituted arylsulfonamide ccr3 antagonists
|
|
HUE025647T2
(en)
|
2009-04-22 |
2016-04-28 |
Axikin Pharmaceuticals Inc |
Arylsulfonamide CCR3 antagonists
|
|
WO2011003870A2
(en)
|
2009-07-06 |
2011-01-13 |
Creabilis S.A. |
Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
|
|
US8486939B2
(en)
|
2009-07-07 |
2013-07-16 |
Pathway Therapeutics Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
|
|
ES2655883T5
(es)
|
2009-07-08 |
2022-04-18 |
Hope Medical Entpr Inc D B A Hope Pharmaceuticals |
Composiciones farmacéuticas que contienen tiosulfato de sodio
|
|
US20110020272A1
(en)
|
2009-07-24 |
2011-01-27 |
Ulrich Schubert |
Combination therapy for treating hepatitis viral infection
|
|
TW201117812A
(en)
|
2009-08-05 |
2011-06-01 |
Idenix Pharmaceuticals Inc |
Macrocyclic serine protease inhibitors
|
|
BR112012003661A2
(pt)
|
2009-08-19 |
2017-04-25 |
Ambit Biosciences Corp |
"compostos de biarila e métodos de uso dos mesmos."
|
|
US8518405B2
(en)
|
2009-10-08 |
2013-08-27 |
The University Of North Carolina At Charlotte |
Tumor specific antibodies and uses therefor
|
|
WO2011050175A1
(en)
|
2009-10-21 |
2011-04-28 |
Sarcode Corporation |
Crystalline pharmaceutical and methods of preparation and use thereof
|
|
US8470817B2
(en)
*
|
2009-10-26 |
2013-06-25 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
|
WO2011056764A1
(en)
|
2009-11-05 |
2011-05-12 |
Ambit Biosciences Corp. |
Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
|
|
WO2011064769A1
(en)
|
2009-11-24 |
2011-06-03 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Methods and pharmaceutical compositions for the treatment of hot flashes
|
|
US20110301235A1
(en)
|
2009-12-02 |
2011-12-08 |
Alquest Therapeutics, Inc. |
Organoselenium compounds and uses thereof
|
|
AR079528A1
(es)
|
2009-12-18 |
2012-02-01 |
Idenix Pharmaceuticals Inc |
Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
|
|
US8710092B2
(en)
*
|
2009-12-23 |
2014-04-29 |
Map Pharmaceuticals, Inc. |
Substituted indolo 4,3 FG quinolines useful for treating migraine
|
|
KR20120125610A
(ko)
|
2009-12-30 |
2012-11-16 |
싸이넥시스, 인크. |
시클로스포린 유사체
|
|
WO2011089166A1
(en)
|
2010-01-19 |
2011-07-28 |
Virologik Gmbh |
Semicarbazone proteasome inhibitors for treating hiv and hepatitis infection
|
|
WO2011094890A1
(en)
|
2010-02-02 |
2011-08-11 |
Argusina Inc. |
Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
|
|
ES2632548T3
(es)
|
2010-02-05 |
2017-09-14 |
Tragara Pharmaceuticals, Inc. |
Formas de estado sólido de los inhibidores de la quinasa macrocíclica
|
|
PL2536706T3
(pl)
|
2010-02-11 |
2017-10-31 |
Celgene Corp |
Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
|
|
US8999995B2
(en)
|
2010-03-02 |
2015-04-07 |
Axikin Pharmaceuticals, Inc. |
Isotopically enriched arylsulfonamide CCR3 antagonists
|
|
WO2011112689A2
(en)
|
2010-03-11 |
2011-09-15 |
Ambit Biosciences Corp. |
Saltz of an indazolylpyrrolotriazine
|
|
US8741894B2
(en)
|
2010-03-17 |
2014-06-03 |
Axikin Pharmaceuticals, Inc. |
Arylsulfonamide CCR3 antagonists
|
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
|
WO2011150201A2
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl amide compounds and methods of use thereof
|
|
CN103153309A
(zh)
|
2010-06-01 |
2013-06-12 |
拜欧赛里克斯公司 |
使用6-环己基-1-羟基-4-甲基-2(1h)-吡啶酮治疗血液恶性肿瘤的方法
|
|
CN104945318A
(zh)
|
2010-06-01 |
2015-09-30 |
拜欧赛里克斯公司 |
羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
|
|
SG186229A1
(en)
|
2010-06-07 |
2013-01-30 |
Novomedix Llc |
Furanyl compounds and the use thereof
|
|
WO2012006677A1
(en)
|
2010-07-14 |
2012-01-19 |
The University Of Queensland |
Patch applying apparatus
|
|
CA2805745C
(en)
|
2010-07-19 |
2019-01-15 |
Summa Health System |
Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
|
|
US20130296363A1
(en)
|
2010-09-01 |
2013-11-07 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
EP2611812A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
Thienopyridin- und thienopyrimidinverbindungen sowie verfahren zu ihrer verwendung
|
|
WO2012030924A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Azolopyridine and azolopyrimidine compounds and methods of use thereof
|
|
WO2012030912A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
7-cyclylquinazoline derivatives and methods of use thereof
|
|
US20120053176A1
(en)
|
2010-09-01 |
2012-03-01 |
Ambit Biosciences Corp. |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
WO2012030913A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
CN103298805A
(zh)
|
2010-09-01 |
2013-09-11 |
埃姆比特生物科学公司 |
喹唑啉化合物及其使用方法
|
|
EP2611793A1
(de)
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cyclochinazolinderivate und verwendungsverfahren dafür
|
|
WO2012030914A1
(en)
|
2010-09-01 |
2012-03-08 |
Ambit Boisciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
US8633209B2
(en)
|
2010-09-01 |
2014-01-21 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
WO2012044641A1
(en)
|
2010-09-29 |
2012-04-05 |
Pathway Therapeutics Inc. |
1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
|
EP2627635A1
(de)
|
2010-10-11 |
2013-08-21 |
Axikin Pharmaceuticals, Inc. |
Salze aus arylsulfonamid-ccr3-antagonisten
|
|
US8901133B2
(en)
|
2010-11-10 |
2014-12-02 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
AU2011338530B2
(en)
|
2010-12-06 |
2017-06-15 |
Follica, Inc. |
Methods for treating baldness and promoting hair growth
|
|
EP2651975B1
(de)
|
2010-12-14 |
2017-08-09 |
National University of Singapore |
Menschlicher monoklonaler antikörper mit spezifität für das dengue-virus-serotyp-1e-protein und verwendungen davon
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
KR20180080358A
(ko)
|
2011-01-10 |
2018-07-11 |
인피니티 파마슈티칼스, 인코포레이티드 |
이소퀴놀린온 및 이의 고체 형태의 제조 방법
|
|
CA2825152A1
(en)
|
2011-01-31 |
2012-08-09 |
Celgene Corporation |
Pharmaceutical compositions of cytidine analogs and methods of use thereof
|
|
WO2012109398A1
(en)
|
2011-02-10 |
2012-08-16 |
Idenix Pharmaceuticals, Inc. |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating hcv infections
|
|
PT2683384E
(pt)
|
2011-03-11 |
2016-03-11 |
Celgene Corp |
Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona
|
|
EP2691388A1
(de)
|
2011-03-28 |
2014-02-05 |
MEI Pharma, Inc. |
(kondensierte arylamino- und heterocyclylamino-)pyrimidynyl und 1,3,5-triazinyl-benzimidazole, pharmazeutische zusammensetzungen daraus und ihre verwendung zur behandlung von proliferativen erkrankungen
|
|
BR112013024909A2
(pt)
|
2011-03-28 |
2019-09-24 |
Mei Pharma Inc |
composto, composição farmacêutica, método para o tratamento, prevenção ou melhoria de um ou mais sintomas de desordem, doença, ou condição mediada por pi3k, e método para modular a atividade enzimática de pi3k
|
|
CA2831582C
(en)
|
2011-03-28 |
2019-01-08 |
Mei Pharma, Inc. |
(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
EP2691409B1
(de)
|
2011-03-31 |
2018-02-21 |
Idenix Pharmaceuticals LLC. |
Verbindungen und zusammensetzungen zur behandlung von virusinfektionen
|
|
EP2705013B1
(de)
|
2011-05-04 |
2016-03-30 |
Balance Therapeutics, Inc. |
Pentylentetrazolderivate
|
|
JP2014517076A
(ja)
|
2011-06-23 |
2014-07-17 |
マップ・ファーマシューティカルズ・インコーポレイテッド |
新規のフルオロエルゴリン類似体
|
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
EP2734530A1
(de)
|
2011-07-19 |
2014-05-28 |
Infinity Pharmaceuticals, Inc. |
Heterocyclische verbindungen und ihre verwendung
|
|
CN103998442B
(zh)
|
2011-08-29 |
2016-09-14 |
无限药品股份有限公司 |
杂环化合物及其用途
|
|
AR088441A1
(es)
|
2011-09-12 |
2014-06-11 |
Idenix Pharmaceuticals Inc |
Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
|
|
JP2014526474A
(ja)
|
2011-09-12 |
2014-10-06 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
ウイルス感染の治療のための化合物および薬学的組成物
|
|
US9630979B2
(en)
|
2011-09-29 |
2017-04-25 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
|
AU2012323782B2
(en)
|
2011-10-12 |
2017-04-06 |
Vaxxas Pty Limited |
Delivery device
|
|
EP2768838A1
(de)
|
2011-10-14 |
2014-08-27 |
IDENIX Pharmaceuticals, Inc. |
Substituierte 3 ', 5 '-cyclophosphate von purin-nukleotid-verbindungen und pharmazeutische zusammensetzungen für die behandlung von virusinfektionen
|
|
CA2851155C
(en)
|
2011-10-14 |
2021-02-23 |
Ambit Biosciences Corporation |
Heterocyclic compounds and methods of use thereof
|
|
SG10201509139QA
(en)
|
2011-12-19 |
2015-12-30 |
Map Pharmaceuticals Inc |
Novel iso-ergoline derivatives
|
|
SG10201506202RA
(en)
|
2011-12-21 |
2015-09-29 |
Map Pharmaceuticals Inc |
Novel neuromodulatory compounds
|
|
WO2013130600A1
(en)
|
2012-02-29 |
2013-09-06 |
Ambit Biosciences Corporation |
Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
|
|
AU2013205306B2
(en)
|
2012-03-16 |
2015-09-17 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2013177195A1
(en)
|
2012-05-22 |
2013-11-28 |
Idenix Pharmaceuticals, Inc. |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
|
GEP20176800B
(en)
|
2012-05-22 |
2018-01-10 |
Idenix Pharmaceuticals Llk |
D-amino acid compounds for liver disease
|
|
US9012640B2
(en)
|
2012-06-22 |
2015-04-21 |
Map Pharmaceuticals, Inc. |
Cabergoline derivatives
|
|
RU2658015C2
(ru)
|
2012-07-25 |
2018-06-19 |
Саркоуд Байосайенс Инк. |
Ингибитор ассоциированного с функцией лимфоцитов антигена-1 (lfa-1), способы его получения и его полиморф
|
|
PT2882441T
(pt)
|
2012-08-09 |
2020-06-29 |
Celgene Corp |
Tratamento de doenças associadas à imunidade e inflamatórias
|
|
RS58548B1
(sr)
|
2012-08-09 |
2019-05-31 |
Celgene Corp |
Čvrsta forma (s)-3-(4-((4-(morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-dion hidrohlorida
|
|
CA2922849A1
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
|
KR20150053906A
(ko)
|
2012-09-07 |
2015-05-19 |
액시킨 파마수티컬스 인코포레이티드 |
동위원소 농축 아릴설폰아미드 ccr3 길항제
|
|
WO2014055647A1
(en)
|
2012-10-03 |
2014-04-10 |
Mei Pharma, Inc. |
(sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
|
|
CN111848711A
(zh)
|
2012-10-08 |
2020-10-30 |
埃迪尼克斯医药有限责任公司 |
用于hcv感染的2′-氯核苷类似物
|
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
|
IL291945B2
(en)
|
2012-11-01 |
2025-11-01 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
WO2014074765A2
(en)
|
2012-11-08 |
2014-05-15 |
Summa Health System |
Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
|
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
|
EP2938624A1
(de)
|
2012-11-14 |
2015-11-04 |
IDENIX Pharmaceuticals, Inc. |
D-alaninester von sp-nukleosidanalogon
|
|
CN107698470A
(zh)
|
2012-11-30 |
2018-02-16 |
诺沃梅迪科斯有限公司 |
取代的二芳基磺酰胺及其用途
|
|
US9211300B2
(en)
|
2012-12-19 |
2015-12-15 |
Idenix Pharmaceuticals Llc |
4′-fluoro nucleosides for the treatment of HCV
|
|
CA2895829A1
(en)
|
2012-12-21 |
2014-06-26 |
Map Pharmaceuticals, Inc. |
Novel methysergide derivatives
|
|
AU2014205324A1
(en)
|
2013-01-11 |
2015-07-30 |
Mayo Foundation For Medical Education And Research |
Vitamins C and K for treating polycystic diseases
|
|
JP6499591B2
(ja)
|
2013-02-25 |
2019-04-10 |
シナジー ファーマシューティカルズ インコーポレイテッド |
結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
|
|
EP2970358B1
(de)
|
2013-03-04 |
2021-06-30 |
Idenix Pharmaceuticals LLC |
3'-deoxy-nukleoside zur behandlung von hcv
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
JP2016514671A
(ja)
|
2013-03-15 |
2016-05-23 |
シナジー ファーマシューティカルズ インコーポレイテッド |
グアニル酸シクラーゼのアゴニストおよびその使用
|
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
|
SG10201709926VA
(en)
|
2013-05-30 |
2017-12-28 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
|
WO2014197578A1
(en)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucleosides for the treatment of hcv
|
|
EP3027636B1
(de)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotide of halogenierte pyrimidine verbindungen für leber krankheiten
|
|
EP3039021A1
(de)
|
2013-08-30 |
2016-07-06 |
Ambit Biosciences Corporation |
Biaryl-acetamid-verbindungen und verfahren zur verwendung davon
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015051336A1
(en)
|
2013-10-03 |
2015-04-09 |
David Wise |
Compositions and methods for treating pelvic pain and other conditions
|
|
MX389256B
(es)
|
2013-10-04 |
2025-03-20 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos.
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
CA2926691A1
(en)
|
2013-10-10 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
|
|
US20160244452A1
(en)
|
2013-10-21 |
2016-08-25 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
EP3063165A1
(de)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanin-phosphoramidat-pronukleotide von 2'-methyl-2'-fluor-guanosin-nukleosid-verbindungen zur behandlung von hcv
|
|
KR20160099090A
(ko)
|
2013-11-27 |
2016-08-19 |
아이데닉스 파마슈티칼스 엘엘씨 |
간암의 치료를 위한 뉴클레오티드
|
|
WO2015081297A1
(en)
|
2013-11-27 |
2015-06-04 |
Idenix Pharmaceuticals, Inc. |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
|
WO2015183346A2
(en)
|
2014-01-31 |
2015-12-03 |
Washington University |
Imaging and treatment of pathophysiologic conditions by cerenkov radiation
|
|
US20170066779A1
(en)
|
2014-03-05 |
2017-03-09 |
Idenix Pharmaceuticals Llc |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
EP4066834A1
(de)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclische verbindungen zur verwendung in der behandlung von pi3k-gamma-vermittelten erkrankungen
|
|
EP3119762B9
(de)
|
2014-03-20 |
2021-10-20 |
Capella Therapeutics, Inc. |
Benzimidazolderivate als erbb-tyrosinkinasehemmer zur behandlung von krebs
|
|
KR102409739B1
(ko)
|
2014-03-20 |
2022-06-17 |
카펠라 테라퓨틱스, 인크. |
암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
|
|
AU2015243437B2
(en)
|
2014-04-09 |
2019-08-29 |
Siteone Therapeutics, Inc. |
10',11'-modified saxitoxins useful for the treatment of pain
|
|
WO2015161137A1
(en)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
|
MX2016014731A
(es)
|
2014-05-12 |
2017-05-04 |
Conatus Pharmaceuticals Inc |
Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
|
|
CA2947939A1
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals Llc |
Nucleoside derivatives for the treatment of cancer
|
|
US9974870B2
(en)
|
2014-06-09 |
2018-05-22 |
Washington University |
Compositions and methods for treatment and imaging using nanoparticles
|
|
US9527815B2
(en)
|
2014-06-18 |
2016-12-27 |
Biotheryx, Inc. |
Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
|
|
PE20170268A1
(es)
|
2014-06-19 |
2017-04-21 |
Ariad Pharma Inc |
Compuestos de heteroarilo para la inhibicion de cinasa
|
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
EP3783034A1
(de)
|
2014-07-23 |
2021-02-24 |
Ohio State Innovation Foundation |
Verfahren und zusammensetzungen im zusammenhang mit antikörperfragmenten zur bindung an das tumorassoziierte glycoprotein 72 (tag 72)
|
|
WO2016014939A1
(en)
|
2014-07-24 |
2016-01-28 |
Washington University |
Compositions targeting radiation-induced molecules and methods of use thereof
|
|
CN106999593A
(zh)
|
2014-09-12 |
2017-08-01 |
妥必徕疗治公司 |
用于纤维化治疗的赛尼克韦罗组合疗法
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
RS60737B1
(sr)
|
2014-10-21 |
2020-09-30 |
Ariad Pharma Inc |
Kristalni oblici 5-hloro-n4-[-2-(dimetilfosforil)fenil]-n2-{2-metoksi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidin-2,4-diamina
|
|
WO2016065264A1
(en)
|
2014-10-24 |
2016-04-28 |
Biogen Ma Inc. |
Diterpenoid derivatives and methods of use thereof
|
|
CN107250116B
(zh)
|
2014-12-23 |
2020-10-27 |
艾士盟医疗公司 |
3,5-二氨基吡唑激酶抑制剂
|
|
WO2016118541A1
(en)
|
2015-01-20 |
2016-07-28 |
Xoc Pharmaceuticals, Inc |
Ergoline compounds and uses thereof
|
|
JP2018502889A
(ja)
|
2015-01-20 |
2018-02-01 |
エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ |
イソエルゴリン化合物およびその使用
|
|
US11147954B2
(en)
|
2015-02-02 |
2021-10-19 |
Vaxxas Pty Limited |
Microprojection array applicator and method
|
|
CN108368147A
(zh)
|
2015-05-27 |
2018-08-03 |
南方研究院 |
用于治疗癌症的核苷酸
|
|
MX390795B
(es)
|
2015-06-23 |
2025-03-21 |
Neurocrine Biosciences Inc |
Inhibidores de transportador de monoamina vesicular tipo 2 (vmat2) para tratar enfermedades o trastornos neurologicos.
|
|
JP6630742B2
(ja)
|
2015-08-17 |
2020-01-15 |
クラ オンコロジー， インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
|
|
EP4548979A3
(de)
|
2015-09-11 |
2025-07-23 |
Nascent Biotech, Inc. |
Verbesserte abgabe von medikamenten an das gehirn
|
|
CN108349985A
(zh)
|
2015-09-14 |
2018-07-31 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US11103259B2
(en)
|
2015-09-18 |
2021-08-31 |
Vaxxas Pty Limited |
Microprojection arrays with microprojections having large surface area profiles
|
|
EP3355981B1
(de)
|
2015-09-28 |
2025-11-19 |
Vaxxas Pty Limited |
Mikroprojektionsanordnungen mit verbesserten hautdurchdringenden eigenschaften und verfahren dafür
|
|
EP3356370B1
(de)
|
2015-09-30 |
2021-08-18 |
Siteone Therapeutics, Inc. |
11,13-modifizierte saxitoxine zur behandlung von schmerzen
|
|
CN115304596A
(zh)
|
2015-10-30 |
2022-11-08 |
纽罗克里生物科学有限公司 |
Valbenazine盐及其多晶形物
|
|
WO2017079566A1
(en)
|
2015-11-05 |
2017-05-11 |
Conatus Pharmaceuticals, Inc. |
Caspase inhibitors for use in the treatment of liver cancer
|
|
US10112924B2
(en)
|
2015-12-02 |
2018-10-30 |
Astraea Therapeutics, Inc. |
Piperdinyl nociceptin receptor compounds
|
|
CA3006966A1
(en)
|
2015-12-02 |
2017-06-08 |
Astraea Therapeutics, Llc |
Piperidinyl nociceptin receptor compounds
|
|
SI3394057T1
(sl)
|
2015-12-23 |
2022-06-30 |
Neurocrine Biosciences, Inc. |
Sintetičen postopek za pripravo (S)-(2R,3R,11bR)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1H- pirido(2,1,-a)izokinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
|
|
CN108697663A
(zh)
|
2015-12-31 |
2018-10-23 |
科内图斯医药公司 |
在肝病治疗中使用胱天蛋白酶抑制剂的方法
|
|
WO2017120446A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
|
|
WO2017120415A1
(en)
|
2016-01-08 |
2017-07-13 |
Celgene Corporation |
Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
|
|
BR112018013761A2
(pt)
|
2016-01-08 |
2018-12-11 |
Celgene Corp |
compostos antiproliferativos e suas composições farmacêuticas e usos
|
|
JP2019506383A
(ja)
|
2016-01-11 |
2019-03-07 |
シナジー ファーマシューティカルズ インコーポレイテッド |
潰瘍性大腸炎を治療するための製剤および方法
|
|
US10759806B2
(en)
|
2016-03-17 |
2020-09-01 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
|
|
EP3442940A1
(de)
|
2016-04-11 |
2019-02-20 |
Clexio Biosciences Ltd. |
Deuterierte ketaminderivate
|
|
US10047077B2
(en)
|
2016-04-13 |
2018-08-14 |
Skyline Antiinfectives, Inc. |
Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
|
|
WO2017184968A1
(en)
|
2016-04-22 |
2017-10-26 |
Kura Oncology, Inc. |
Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
|
|
WO2017190086A1
(en)
|
2016-04-29 |
2017-11-02 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
TWI753910B
(zh)
|
2016-05-16 |
2022-02-01 |
美商拜歐斯瑞克斯公司 |
吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
|
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2018049080A1
(en)
|
2016-09-07 |
2018-03-15 |
Fgh Biotech, Inc. |
Di-substituted pyrazole compounds for the treatment of diseases
|
|
JP2019529419A
(ja)
|
2016-09-19 |
2019-10-17 |
エムイーアイ ファーマ，インク． |
併用療法
|
|
EP3534885B1
(de)
|
2016-11-03 |
2021-01-20 |
Kura Oncology, Inc. |
Farnesyltransferase-inhibitoren zur verwendung bei der behandlung von krebs
|
|
CN117069622A
(zh)
|
2016-11-09 |
2023-11-17 |
诺沃梅迪科斯有限公司 |
1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
|
|
WO2018089692A1
(en)
|
2016-11-09 |
2018-05-17 |
Phloronol, Inc. |
Eckol derivatives, methods of synthesis and uses thereof
|
|
JP7105774B2
(ja)
|
2016-12-01 |
2022-07-25 |
イグナイタ インコーポレイテッド |
がん治療のための方法
|
|
WO2018102673A1
(en)
|
2016-12-02 |
2018-06-07 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
MY199695A
(en)
|
2017-01-27 |
2023-11-18 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
US10137121B2
(en)
|
2017-02-21 |
2018-11-27 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
KR20200090982A
(ko)
|
2017-02-21 |
2020-07-29 |
쿠라 온콜로지, 인크. |
파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
|
KR20190127699A
(ko)
|
2017-03-27 |
2019-11-13 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암 치료 조성물 및 방법
|
|
KR20200012833A
(ko)
|
2017-03-29 |
2020-02-05 |
사이트원 테라퓨틱스, 인코포레이티드 |
통증 치료용 11,13-개질된 색시톡신
|
|
WO2018183782A1
(en)
|
2017-03-29 |
2018-10-04 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
AU2018241251B2
(en)
|
2017-03-31 |
2024-06-27 |
Vaxxas Pty Limited |
Device and method for coating surfaces
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
JOP20190219A1
(ar)
|
2017-05-09 |
2019-09-22 |
Cardix Therapeutics LLC |
تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
|
|
US10085999B1
(en)
|
2017-05-10 |
2018-10-02 |
Arixa Pharmaceuticals, Inc. |
Beta-lactamase inhibitors and uses thereof
|
|
EP3624795B1
(de)
|
2017-05-19 |
2022-04-20 |
NFlection Therapeutics, Inc. |
Kondensierte heteroaromatenanilinverbindungen zur behandlung von hauterkrankungen
|
|
ES3030506T3
(en)
|
2017-05-19 |
2025-06-30 |
Nflection Therapeutics Inc |
Pyrrolopyridine-aniline compounds for treatment of dermal disorders
|
|
MX2019014272A
(es)
|
2017-06-01 |
2020-12-11 |
Xoc Pharmaceuticals Inc |
Compuestos policiclicos y usos de los mismos.
|
|
US11175128B2
(en)
|
2017-06-13 |
2021-11-16 |
Vaxxas Pty Limited |
Quality control of substrate coatings
|
|
CA3071680A1
(en)
|
2017-08-04 |
2019-02-07 |
Vaxxas Pty Limited |
Compact high mechanical energy storage and low trigger force actuator for the delivery of microprojection array patches (map)
|
|
MX2020001207A
(es)
|
2017-08-07 |
2020-03-20 |
Kura Oncology Inc |
Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
|
|
US10806730B2
(en)
|
2017-08-07 |
2020-10-20 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
DK3684333T3
(da)
|
2017-09-21 |
2025-05-12 |
Neurocrine Biosciences Inc |
Valbenazin-formulering med høj dosis og sammensætninger, fremgangsmåder og kits relateret hertil
|
|
MX2020004133A
(es)
|
2017-10-04 |
2020-08-13 |
Univ California |
Oligosacaridos inmunomoduladores.
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
US20200230127A1
(en)
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
WO2019113269A1
(en)
|
2017-12-08 |
2019-06-13 |
Kura Oncology, Inc. |
Methods of treating cancer patients with farnesyltransferase inhibitors
|
|
WO2019139869A1
(en)
|
2018-01-10 |
2019-07-18 |
Cura Therapeutics Llc |
Pharmaceutical compositions comprising phenylsulfonamides, and their therapeutic applications
|
|
US20210052529A1
(en)
|
2018-01-10 |
2021-02-25 |
Cura Therapeutics, Llc |
Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
|
|
MX2020013004A
(es)
|
2018-06-14 |
2021-02-17 |
Neurocrine Biosciences Inc |
Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
|
|
CA3105352A1
(en)
|
2018-06-29 |
2020-01-02 |
Histogen, Inc. |
(s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
|
|
BR112021000019A2
(pt)
|
2018-08-15 |
2021-04-06 |
Neurocrine Biosciences Inc. |
Métodos para administração de certos inibidores de vmat2
|
|
WO2020072835A1
(en)
|
2018-10-03 |
2020-04-09 |
Siteone Therapeutics, Inc. |
11,13-modified saxitoxins for the treatment of pain
|
|
CA3117968A1
(en)
|
2018-11-01 |
2020-05-07 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
MA55141A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés cyanoaryl-aniline pour le traitement d'affections de la peau
|
|
MA55148A
(fr)
|
2018-11-20 |
2021-09-29 |
Nflection Therapeutics Inc |
Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
|
|
CA3120351A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Aryl-aniline and heteroaryl-aniline compounds for treatment of skin cancers
|
|
CA3120337A1
(en)
|
2018-11-20 |
2020-05-28 |
Nflection Therapeutics, Inc. |
Naphthyridinone-aniline compounds for treatment of dermal disorders
|
|
US12391705B2
(en)
|
2018-12-19 |
2025-08-19 |
Shy Therapeutics, Llc |
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
CA3124616A1
(en)
|
2018-12-21 |
2020-06-25 |
Kura Oncology, Inc. |
Therapies for squamous cell carcinomas
|
|
WO2020132700A1
(en)
|
2018-12-21 |
2020-06-25 |
Fgh Biotech Inc. |
Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
|
|
TWI839461B
(zh)
|
2019-02-06 |
2024-04-21 |
美商戴斯阿爾法股份有限公司 |
Il-17a調節物及其用途
|
|
US20220142983A1
(en)
|
2019-03-01 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
JP7645192B2
(ja)
|
2019-03-07 |
2025-03-13 |
ノボ メディシン インク． |
カスパーゼ阻害剤及びその使用方法
|
|
US20220143006A1
(en)
|
2019-03-15 |
2022-05-12 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
JP7641232B2
(ja)
|
2019-03-29 |
2025-03-06 |
クラ オンコロジー， インコーポレイテッド |
ファルネシルトランスフェラーゼ阻害剤による扁平上皮癌の治療方法
|
|
WO2020205387A1
(en)
|
2019-04-01 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating cancer with farnesyltransferase inhibitors
|
|
WO2020223583A1
(en)
|
2019-05-02 |
2020-11-05 |
Kura Oncology, Inc. |
Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
|
|
EP3996813A1
(de)
|
2019-07-11 |
2022-05-18 |
Cura Therapeutics, LLC |
Phenylverbindungen und pharmazeutische zusammensetzungen davon sowie deren therapeutische anwendungen
|
|
CA3146157A1
(en)
|
2019-07-11 |
2021-01-14 |
Cura Therapeutics, Llc |
Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
|
|
TW202532387A
(zh)
|
2019-07-26 |
2025-08-16 |
美商艾斯佩維他治療學公司 |
官能化的長鏈烴一元及二元羧酸及其用於預防或治療疾病的用途
|
|
US11788091B2
(en)
|
2019-08-21 |
2023-10-17 |
University Of Virginia Patent Foundation |
Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
|
|
US12319967B2
(en)
|
2019-08-21 |
2025-06-03 |
University Of Virginia Patent Foundation |
Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
JP7566889B2
(ja)
|
2019-09-16 |
2024-10-15 |
ダイス・アルファ・インコーポレイテッド |
Ｉｌ－１７ａモジュレーターおよびその使用
|
|
US20230008367A1
(en)
|
2019-09-26 |
2023-01-12 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
EP4037687B1
(de)
|
2019-10-01 |
2025-10-29 |
Molecular Skin Therapeutics, Inc. |
Benzoxazinon-verbindungen als duale klk5/7-inhibitoren
|
|
CA3179635A1
(en)
|
2020-05-29 |
2021-12-02 |
Boulder Bioscience Llc |
Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
|
|
EP4168414A1
(de)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
|
|
EP4149471A4
(de)
|
2020-06-30 |
2024-07-10 |
Prosetta Biosciences, Inc. |
Isochinolinderivate, verfahren zur synthese und verwendungen davon
|
|
MX2023001741A
(es)
|
2020-08-14 |
2023-04-25 |
Siteone Therapeutics Inc |
Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.
|
|
WO2022165000A1
(en)
|
2021-01-27 |
2022-08-04 |
Shy Therapeutics, Llc |
Methods for the treatment of fibrotic disease
|
|
EP4284377A1
(de)
|
2021-01-27 |
2023-12-06 |
Shy Therapeutics LLC |
Verfahren zur behandlung von fibrotischen erkrankungen
|
|
WO2022189856A1
(en)
|
2021-03-08 |
2022-09-15 |
Abionyx Pharma Sa |
Compounds useful for treating liver diseases
|
|
WO2022192545A1
(en)
|
2021-03-10 |
2022-09-15 |
Dice Molecules Sv, Inc. |
Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
|
|
WO2022226166A1
(en)
|
2021-04-22 |
2022-10-27 |
Protego Biopharma, Inc. |
Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
|
|
WO2022251533A1
(en)
|
2021-05-27 |
2022-12-01 |
Protego Biopharma, Inc. |
Heteroaryl diamide ire1/xbp1s activators
|
|
US12017997B2
(en)
|
2021-10-22 |
2024-06-25 |
Prosetta Biosciences, Inc. |
Host-targeted pan-respiratory antiviral small molecule therapeutics
|
|
AU2022399572A1
(en)
|
2021-11-30 |
2024-05-02 |
Kura Oncology, Inc. |
Macrocyclic compounds having farnesyltransferase inhibitory activity
|
|
WO2023129577A1
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Cyclic thiol prodrugs
|
|
WO2023129576A2
(en)
|
2022-01-03 |
2023-07-06 |
Lilac Therapeutics, Inc. |
Acyclic thiol prodrugs
|
|
US12168673B2
(en)
|
2022-03-02 |
2024-12-17 |
Mitopower, Inc. |
Prodrugs derived from nicotinic acid and ribose
|
|
JP2025511122A
(ja)
|
2022-03-28 |
2025-04-15 |
アイソステリックス， インコーポレイテッド |
リジンアセチルトランスフェラーゼのｍｙｓｔファミリーの阻害剤
|
|
WO2023192904A1
(en)
|
2022-03-30 |
2023-10-05 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
GB2619907A
(en)
|
2022-04-01 |
2023-12-27 |
Kanna Health Ltd |
Novel crystalline salt forms of mesembrine
|
|
US12187699B2
(en)
|
2022-04-14 |
2025-01-07 |
Bristol-Myers Squibb Company |
GSPT1 compounds and methods of use of the novel compounds
|
|
CN119156456A
(zh)
|
2022-04-15 |
2024-12-17 |
新基公司 |
预测淋巴瘤对药物的反应性的方法以及治疗淋巴瘤的方法
|
|
CR20240512A
(es)
|
2022-04-25 |
2025-03-03 |
Siteone Therapeutics Inc |
Inhibidores de amida heterocíclica bicíclica de sodio activado por voltaje 1.8 (nav1.8) para el tratamiento del dolor
|
|
EP4519439A1
(de)
|
2022-05-05 |
2025-03-12 |
BioMarin Pharmaceutical Inc. |
Verfahren zur behandlung von duchenne-muskeldystrophie
|
|
KR20250099113A
(ko)
|
2022-09-09 |
2025-07-01 |
이노보 테라퓨틱스 인코포레이티드 |
CK1α 및 DUAL CK1α/GSPT1 분해 화합물
|
|
WO2024073473A1
(en)
|
2022-09-30 |
2024-04-04 |
Boulder Bioscience Llc |
Compositions comprising 3,3'-diindolylmethane for treating non-hemorrhagic closed head injury
|
|
EP4605084A2
(de)
|
2022-10-18 |
2025-08-27 |
Eluciderm Inc. |
2-substituierte 3,4a, 5,7,8, 8a-hexahydro-4h-thiopeno [4,3-d]pyrimidin-4-one zur wundbehandlung
|
|
WO2024092037A1
(en)
|
2022-10-26 |
2024-05-02 |
Protego Biopharma, Inc. |
Spirocycle containing pyridone compounds
|
|
EP4608839A1
(de)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocyclen mit bicyclischen heteroarylverbindungen
|
|
EP4608834A1
(de)
|
2022-10-26 |
2025-09-03 |
Protego Biopharma, Inc. |
Spirocyclen enthaltende pyridinverbindungen
|
|
WO2024118801A1
(en)
|
2022-11-30 |
2024-06-06 |
Protego Biopharma, Inc. |
Linear heteroaryl diamide ire1/xbp1s activators
|
|
EP4626865A1
(de)
|
2022-11-30 |
2025-10-08 |
Protego Biopharma, Inc. |
Cyclische pyrazoldiamid-ire1/xbp1s-aktivatoren
|
|
AU2023418987A1
(en)
|
2022-12-30 |
2025-07-03 |
Altay Therapeutics, Inc. |
2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors
|
|
EP4702143A2
(de)
|
2023-04-24 |
2026-03-04 |
BioMarin Pharmaceutical Inc. |
Zusammensetzungen und verfahren zur behandlung von stxbp1-erkrankungen
|
|
US20240368596A1
(en)
|
2023-05-05 |
2024-11-07 |
Biomarin Pharmaceutical Inc. |
Dystrophin exon skipping oligonucleotides
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
WO2025072489A2
(en)
|
2023-09-27 |
2025-04-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
|
|
TW202530223A
(zh)
|
2023-09-27 |
2025-08-01 |
美商艾索司特瑞克斯公司 |
Ｍｙｓｔ抑制劑
|
|
WO2025085416A1
(en)
|
2023-10-16 |
2025-04-24 |
Bristol-Myers Squibb Company |
Gspt1 compounds and methods of use of the compounds
|
|
WO2025085878A1
(en)
|
2023-10-20 |
2025-04-24 |
Altay Therapeutics, Inc. |
N-phenyl-3-(2,5-dioxopyrrolidin-1-yl)propanamide derivatives and similar compounds as dux4 inhibitors for the treatment of e.g. neuromuscular disorders
|
|
WO2025102082A1
(en)
|
2023-11-10 |
2025-05-15 |
Altay Therapeutics, Inc. |
Carbocyclic and heterocyclic stat3 inhibitor compositions and methods
|
|
GB2636969A
(en)
|
2023-11-24 |
2025-07-09 |
Ontrack Therapeutics Ltd |
Novel crystalline salt forms
|
|
WO2025147691A1
(en)
|
2024-01-04 |
2025-07-10 |
Innovo Therapeutics, Inc. |
Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
|
|
WO2025160286A1
(en)
|
2024-01-24 |
2025-07-31 |
Siteone Therapeutics, Inc. |
2-aryl cycloalkyl and heterocycloalkyl inhibitors of nav1.8 for the treatment of pain
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025221809A1
(en)
|
2024-04-16 |
2025-10-23 |
Eluciderm Inc. |
2-aryl-quinazolin-4(3h)-one inhibitors for the treatment of diseases
|
|
WO2025240895A1
(en)
|
2024-05-17 |
2025-11-20 |
Siteone Therapeutics, Inc. |
SUBSTITUTED CYCLOALKYL AND HETEROCYCLOALKYL INHIBITORS OF NAv1.8 FOR THE TREATMENT OF PAIN
|
|
WO2025255341A1
(en)
|
2024-06-05 |
2025-12-11 |
Protego Biopharma, Inc. |
Tetrahydrofuranyl ire1/xbp1s activators
|
|
WO2026013449A2
(en)
|
2024-07-11 |
2026-01-15 |
Sea4Us - Biotecnologia E Recursos Marinhos, Sa |
Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain
|